Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-10
DOI
10.3389/fphar.2021.674559
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker
- (2020) Lina Luo et al. ANALYTICAL CHEMISTRY
- Differences in metformin and thiamine uptake between human and mouse organic cation transporter OCT1: structural determinants and potential consequences for intrahepatic concentrations
- (2020) Marleen J. Meyer et al. DRUG METABOLISM AND DISPOSITION
- OCTN2-Mediated Acetyl-l-Carnitine Transport in Human Pulmonary Epithelial Cells In Vitro
- (2019) Johanna J. Salomon et al. Pharmaceutics
- Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans
- (2019) Ole Jensen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of cycloguanil, the active metabolite of the antimalarial drug proguanil
- (2018) Johannes Matthaei et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content
- (2018) Xiaomin Liang et al. PLOS BIOLOGY
- Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
- (2018) Xiaoyan Chu et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions
- (2017) Xiaoyan Chu et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokinetics
- (2016) J Matthaei et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1
- (2016) SW Yee et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Role of organic cation transporters in drug–drug interaction
- (2015) Hermann Koepsell Expert Opinion on Drug Metabolism & Toxicology
- An LC-MS/MS method to quantify acylcarnitine species including isomeric and odd-numbered forms in plasma and tissues
- (2015) Pieter Giesbertz et al. JOURNAL OF LIPID RESEARCH
- Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1
- (2015) Tina Seitz et al. Genome Medicine
- OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin
- (2014) Ligong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration
- (2013) Mladen V. Tzvetkov et al. BIOCHEMICAL PHARMACOLOGY
- Identification of Novel Substrates and Structure–Activity Relationship of Cellular Uptake Mediated by Human Organic Cation Transporters 1 and 2
- (2013) Ramon Hendrickx et al. JOURNAL OF MEDICINAL CHEMISTRY
- The SLC22 family with transporters of organic cations, anions and zwitterions
- (2013) Hermann Koepsell MOLECULAR ASPECTS OF MEDICINE
- OCT1 genetic variants influence the pharmacokinetics of morphine in children
- (2013) Tsuyoshi Fukuda et al. PHARMACOGENOMICS
- The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1
- (2012) Ali R. Saadatmand et al. BIOCHEMICAL PHARMACOLOGY
- Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol
- (2011) M V Tzvetkov et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Human metabolic individuality in biomedical and pharmaceutical research
- (2011) Karsten Suhre et al. NATURE
- The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
- (2009) M V Tzvetkov et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
- (2009) Anne T. Nies et al. HEPATOLOGY
- Human Urinary Metabolomic Profile of PPARα Induced Fatty Acid β-Oxidation
- (2009) Andrew D. Patterson et al. JOURNAL OF PROTEOME RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation